Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Atea PharmaceuticalsAVIR +5.21%24 EV-to-OCF is -1.11 as of Aug. 08, 2026. GuruFocus rates AVIR with a GF Score™ of 24/100. The stock has 3 warning signs investors should review. Among 1,409 Biotechnology companies, Atea Pharmaceuticals ranks worse than 64.09% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Atea Pharmaceuticals's Enterprise Value is $164.77 Mil.
Atea Pharmaceuticals's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was $-147.86 Mil. Therefore, Atea Pharmaceuticals's EV-to-OCF for today is -1.11.
The historical rank and industry rank for Atea Pharmaceuticals's EV-to-OCF or its related term are showing as below:
AVIR'
s EV-to-OCF Range Over the Past 10 Years
Min: -1.13 Med: 2.12 Max: 21.04
Current: -1.11
During the past 8 years, the highest EV-to-OCF of Atea Pharmaceuticals was 21.04. The lowest was -1.13. And the median was 2.12.
AVIR's EV-to-OCF is ranked worse than 64.09% of 1409
companies
in the Biotechnology industry
Industry Median: -3.48
vs AVIR: -1.11
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Atea Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
Atea Pharmaceuticals's share price for today is $5.27.
Atea Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.110.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Atea Pharmaceuticals EV-to-OCF Related Terms
Atea Pharmaceuticals EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Atea Pharmaceuticals's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Atea Pharmaceuticals's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Atea Pharmaceuticals EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Atea Pharmaceuticals's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Atea Pharmaceuticals's EV-to-OCF falls into.
Atea Pharmaceuticals's current Enterprise Value is $164.77 Mil.
Atea Pharmaceuticals's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-147.86 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Atea Pharmaceuticals (AVIR) has a EV-to-OCF of -1.11 as of Aug. 08, 2026. According to the industry distribution chart, Atea Pharmaceuticals ranks #903 out of 1409 companies in the Biotechnology industry, placing it in the top 64.1%.
Is Atea Pharmaceuticals' EV-to-OCF too high?
Atea Pharmaceuticals' current EV-to-OCF is -1.11. Based on the distribution chart, Atea Pharmaceuticals ranks #903 out of 1409 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Atea Pharmaceuticals has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Atea Pharmaceuticals' EV-to-OCF compare to STRO and IPSC?
According to the Biotechnology industry distribution chart, Atea Pharmaceuticals ranks #903 out of 1409 companies for EV-to-OCF. This places Atea Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Atea Pharmaceuticals's current EV-to-OCF is -1.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Atea Pharmaceuticals stock overvalued right now?
Atea Pharmaceuticals (AVIR) has a current EV-to-OCF of -1.11. The current EV-to-OCF is -1.11. Atea Pharmaceuticals' overall GF Score™ is 24/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Atea Pharmaceuticals (AVIR), the current EV-to-OCF is -1.11 as of Aug. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.
24GF Score
Get the complete analysis for AVIR
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AVIR has been successfully added to your 
